Literature DB >> 28555885

Serum extracellular vesicles contain protein biomarkers for primary sclerosing cholangitis and cholangiocarcinoma.

Ander Arbelaiz1, Mikel Azkargorta2,3, Marcin Krawczyk4,5, Alvaro Santos-Laso1, Ainhoa Lapitz1, Maria J Perugorria1,3,6, Oihane Erice1, Esperanza Gonzalez7, Raul Jimenez-Agüero1, Adelaida Lacasta1, Cesar Ibarra8, Alberto Sanchez-Campos8, Juan P Jimeno9, Frank Lammert4, Piotr Milkiewicz10,11, Marco Marzioni12, Rocio I R Macias3,13, Jose J G Marin3,13, Tushar Patel14, Gregory J Gores15, Ibon Martinez16, Félix Elortza2,3, Juan M Falcon-Perez3,6,7, Luis Bujanda1,3, Jesus M Banales1,3,6.   

Abstract

Cholangiocarcinoma (CCA) includes a heterogeneous group of biliary cancers with poor prognosis. Several conditions, such as primary sclerosing cholangitis (PSC), are risk factors. Noninvasive differential diagnosis between intrahepatic CCA and hepatocellular carcinoma (HCC) is sometimes difficult. Accurate noninvasive biomarkers for PSC, CCA, and HCC are not available. In the search for novel biomarkers, serum extracellular vesicles (EV) were isolated from CCA (n = 43), PSC (n = 30), or HCC (n = 29) patients and healthy individuals (control, n = 32); and their protein content was characterized. By using nanoparticle tracking analysis, serum EV concentration was found to be higher in HCC than in all the other groups. Round morphology (by transmission electron microscopy), size (∼180 nm diameter by nanoparticle tracking analysis), and markers (clusters of differentiation 9, 63, and 81 by immunoblot) indicated that most serum EV were exosomes. Proteome profiles (by mass spectrometry) revealed multiple differentially expressed proteins among groups. Several of these proteins showed high diagnostic values with maximum area under the receiver operating characteristic curve of 0.878 for CCA versus control, 0.905 for CCA stage I-II versus control, 0.789 for PSC versus control, 0.806 for noncirhottic PSC versus control, 0.796 for CCA versus PSC, 0.956 for CCA stage I-II versus PSC, 0.904 for HCC versus control, and 0.894 for intrahepatic CCA versus HCC. Proteomic analysis of EV derived from CCA human cells in vitro revealed higher abundance of oncogenic proteins compared to EV released by normal human cholangiocytes. Orthotopic implant of CCA human cells in the liver of immunodeficient mice resulted in the release to serum of EV containing some similar human oncogenic proteins.
CONCLUSION: Proteomic signatures found in serum EV of CCA, PSC, and HCC patients show potential usefulness as diagnostic tools. (Hepatology 2017;66:1125-1143).
© 2017 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28555885     DOI: 10.1002/hep.29291

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  77 in total

Review 1.  Cholangiocarcinoma 2020: the next horizon in mechanisms and management.

Authors:  Jesus M Banales; Jose J G Marin; Angela Lamarca; Pedro M Rodrigues; Shahid A Khan; Lewis R Roberts; Vincenzo Cardinale; Guido Carpino; Jesper B Andersen; Chiara Braconi; Diego F Calvisi; Maria J Perugorria; Luca Fabris; Luke Boulter; Rocio I R Macias; Eugenio Gaudio; Domenico Alvaro; Sergio A Gradilone; Mario Strazzabosco; Marco Marzioni; Cédric Coulouarn; Laura Fouassier; Chiara Raggi; Pietro Invernizzi; Joachim C Mertens; Anja Moncsek; Sumera Rizvi; Julie Heimbach; Bas Groot Koerkamp; Jordi Bruix; Alejandro Forner; John Bridgewater; Juan W Valle; Gregory J Gores
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-06-30       Impact factor: 46.802

2.  Cholangiocyte-derived exosomal long noncoding RNA H19 promotes cholestatic liver injury in mouse and humans.

Authors:  Xiaojiaoyang Li; Runping Liu; Zhiming Huang; Emily C Gurley; Xuan Wang; Juan Wang; Hongliang He; Hu Yang; Guanhua Lai; Luyong Zhang; Jasmohan S Bajaj; Melanie White; William M Pandak; Phillip B Hylemon; Huiping Zhou
Journal:  Hepatology       Date:  2018-05-02       Impact factor: 17.425

Review 3.  Cholangiocarcinoma - evolving concepts and therapeutic strategies.

Authors:  Sumera Rizvi; Shahid A Khan; Christopher L Hallemeier; Robin K Kelley; Gregory J Gores
Journal:  Nat Rev Clin Oncol       Date:  2017-10-10       Impact factor: 66.675

4.  Extracellular vesicles in bile: a game changer in the diagnosis of indeterminate biliary stenoses?

Authors:  Seung Bae Yoon; Jae Hyuck Chang
Journal:  Hepatobiliary Surg Nutr       Date:  2017-12       Impact factor: 7.293

Review 5.  Cholangiocarcinoma: novel therapeutic targets.

Authors:  Keisaku Sato; Shannon Glaser; Domenico Alvaro; Fanyin Meng; Heather Francis; Gianfranco Alpini
Journal:  Expert Opin Ther Targets       Date:  2020-02-26       Impact factor: 6.902

Review 6.  Emerging Technologies for the Diagnosis of Perihilar Cholangiocarcinoma.

Authors:  Sumera Rizvi; John Eaton; Ju Dong Yang; Vinay Chandrasekhara; Gregory J Gores
Journal:  Semin Liver Dis       Date:  2018-06-05       Impact factor: 6.115

7.  Amelioration of Ductular Reaction by Stem Cell Derived Extracellular Vesicles in MDR2 Knockout Mice via Lethal-7 microRNA.

Authors:  Kelly McDaniel; Nan Wu; Tianhao Zhou; Li Huang; Keisaku Sato; Julie Venter; Ludovica Ceci; Demeng Chen; Sugeily Ramos-Lorenzo; Pietro Invernizzi; Francesca Bernuzzi; Chaodong Wu; Heather Francis; Shannon Glaser; Gianfranco Alpini; Fanyin Meng
Journal:  Hepatology       Date:  2019-04-12       Impact factor: 17.425

8.  Decoding the Role of Extracellular Vesicles in Liver Diseases.

Authors:  Fengyan Deng; Nancy Magee; Yuxia Zhang
Journal:  Liver Res       Date:  2017-12-07

9.  Acquisition of Cholangiocarcinoma Traits during Advanced Hepatocellular Carcinoma Development in Mice.

Authors:  Liyuan Li; Maoxiang Qian; I-Hsuan Chen; David Finkelstein; Arzu Onar-Thomas; Melissa Johnson; Christopher Calabrese; Armita Bahrami; Dolores H López-Terrada; Jun J Yang; W Andy Tao; Liqin Zhu
Journal:  Am J Pathol       Date:  2017-12-15       Impact factor: 4.307

Review 10.  From NASH to HCC: current concepts and future challenges.

Authors:  Quentin M Anstee; Helen L Reeves; Elena Kotsiliti; Olivier Govaere; Mathias Heikenwalder
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2019-07       Impact factor: 46.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.